| Literature DB >> 34479482 |
Eun Ji Seo1, Joonhwa Hong2, Hyeon-Ju Lee3, Youn-Jung Son4.
Abstract
BACKGROUND: Postoperative atrial fibrillation (POAF) is the most common cardiac dysrhythmia to occur after coronary artery bypass grafting (CABG). However, the risk factors for new-onset POAF after CABG during the perioperative period have yet to be clearly defined. Accordingly, the aim of our systematic review was to evaluate the perioperative predictors of new-onset POAF after isolated CABG.Entities:
Keywords: Atrial fibrillation; Coronary artery bypass graft; Predictor; Systematic review
Mesh:
Year: 2021 PMID: 34479482 PMCID: PMC8414730 DOI: 10.1186/s12872-021-02224-x
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1The flow diagram of the study selection process
Characteristics of included studies (N = 9)
| Authors (publication year)/country | Sample size | Type of CABG | Time to onset of POAF | Sample characteristics | |
|---|---|---|---|---|---|
| New-onset POAF | Sinus rhythm | ||||
| Mendes et al. [ | 168 | On-pump | 3.4 ± 0.2 days after surgery(mean) | N = 57 (33.9%) Mean age: 69.7 years M: 72.0% F: 28.0% | N = 111 (66.1%) Mean age: 62.1 years M: 65.0% F: 35.0% |
| Cerillo et al. [ | 107 | Both | 3 days after surgery (median) | N = 33 (30.8%) Mean age: 70.2 years M: 78.8% F: 21.2% | N = 74 (69.2%) Mean age: 65.8 years M: 68.9% F: 31.1% |
| Zangrillo et al. [ | 160 | Off-pump | Unreported | N = 33 (20.6%) Mean age: 68.0 years M: 87.9% F: 12.1% | N = 127 (79.4%) Mean age: 64.0 years M: 84.3% F: 15.7% |
| Akazawa et al. [ | 150 | Off-pump | 48 h after surgery (mean) | N = 26 (17.3%) Mean age: 71.0 years M: 88.0% F: 12.0% | N = 124 (82.7%) Mean age: 66.0 years M: 79.0% F: 21.0% |
| Wang et al. [ | 197 | Unreported | 4 days after surgery | N = 60 (30.5%) Mean age: 71.0 years M: 68.3% F: 31.7% | N = 137 (69.5%) Mean age: 64.0 years M: 69.3% F: 30.7% |
| Koolen et al. [ | 3148 | Both | Unreported | N = 1080 (34.3%) Mean age: 69.8 years M: 77.0% F: 23.0% | N = 2068 (65.7%) Mean age: 64.7 years M: 79.0% F: 21.0% |
| Tsai et al. [ | 266 | Both | Unreported | N = 126 (47.4%) Mean age: 69.9 years M: 71.4% F: 28.6% | N = 140 (52.6%) Mean age: 61.8 years M: 82.1% F: 17.9% |
| Vlahou et al. [ | 446 | On-pump | Unreported | N = 111 (24.9%) Mean age: 68.1 years M: 83.8% F: 16.2% | N = 335 (75.1%) Mean age: 63.5 years M: 85.9% F: 14.1% |
| Daie et al. [ | 156 | Unreported | Unreported | N = 29 (18.6%) Mean age: 63.9 years M: 62.1% F: 37.9% | N = 127 (81.4%) Mean age: 61.2 years M: 68.5% F: 31.5% |
CABG, coronary artery bypass grafting; F, female; M, male; POAF, postoperative atrial fibrillation
Pooled odds ratio or standardized mean difference of risk factors
| Risk factors | No. of study | OR/SMD (95% CI) | Z value | I2% (p) | Egger’s test, p | |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age (years) | 8 | 1.10 (0.62–1.59) | 4.46 | < 0.001 | 0.0 (0.811) | 0.658 |
| Male | 9 | 0.92 (0.79–1.08) | − 1.01 | 0.313 | 1.9 (0.419) | 0.367 |
| Female | 9 | 1.08 (0.93–1.27) | 1.01 | 0.313 | 1.9 (0.419) | 0.367 |
| BMI (kg/m2) | 3 | − 0.03 (− 0.10 to 0.04) | − 0.82 | 0.412 | 0.0 (0.956) | 0.262 |
| Clinical characteristics | ||||||
| Mg++ (mg/dL) | 2 | − 0.37 (− 0.84 to 0.10) | − 1.55 | 0.121 | 74.9 (0.046) | NA |
| Ca++ (mg/dL) | 2 | − 0.91 (− 0.30 to 0.12) | − 0.86 | 0.398 | 0.0 (0.528) | NA |
| Serum Cr (mg/dL) | 3 | 0.12 (0.05–0.19) | 3.39 | 0.001 | 0.0 (0.826) | 0.636 |
| Hemoglobin (mg/dL) | 3 | − 0.10 (− 0.17 to − 0.03) | − 2.71 | 0.007 | 0.0 (0.846) | 0.825 |
| LVEF (%) | 6 | − 0.43 (− 0.43 to − 0.27) | − 3.43 | 0.001 | 71.4 (0.004) | 0.553 |
| Beta-blockers | 8 | 0.89 (0.68–1.17) | − 0.83 | 0.405 | 35.9 (0.142) | 0.260 |
| ACEi | 3 | 1.05 (0.91–1.21) | 0.62 | 0.535 | 0.0 (0.927) | 0.375 |
| ACEi/ARB | 2 | 0.43 (0.12–1.54) | − 1.30 | 0.195 | 65.4 (0.089) | NA |
| Nitrates | 2 | 1.63 (0.86–3.02) | 1.54 | 0.124 | 0.0 (0.528) | NA |
| Diuretics | 2 | 1.33 (0.69–2.55) | 0.86 | 0.390 | 0.0 (0.912) | NA |
| Statin | 2 | 1.02 (0.57–1.82) | 0.05 | 0.959 | 0.0 (0.367) | NA |
| CCB | 4 | 1.22 (0.92–1.61) | 1.37 | 0.171 | 19.8 (0.291) | 0.310 |
| Comorbidities | ||||||
| MI | 5 | 1.37 (0.96–1.96) | 1.71 | 0.088 | 39.8 (0.156) | 0.326 |
| Essential hypertension | 8 | 1.33 (1.62–1.52) | 4.13 | < 0.001 | 0.0 (0.581) | 0.359 |
| Diabetes | 8 | 1.23 (0.96–1.56) | 1.67 | 0.095 | 37.9 (0.127) | 0.308 |
| COPD | 5 | 1.66 (1.13–2.43) | 2.59 | 0.010 | 0.0 (0.494) | 0.759 |
| Renal failure | 3 | 1.70 (1.14–2.55) | 2.60 | 0.009 | 0.0 (0.928) | 0.766 |
| Dyslipidemia | 4 | 1.47 (0.78–2.76) | 1.20 | 0.232 | 82.2 (0.001) | 0.225 |
| Stroke | 2 | 1.08 (0.58–2.00) | 0.24 | 0.813 | 0.0 (0.708) | NA |
| CVD | 2 | 1.60 (0.93–2.75) | 1.68 | 0.628 | 0.0 (0.428) | NA |
| Number of grafts | 5 | − 0.09 (− 0.29 to 0.11) | − 0.86 | 0.393 | 49.3 (0.096) | 0.500 |
| Cross-clamp time (min) | 4 | 0.06 (− 0.08 to 0.20) | 0.82 | 0.415 | 1.1 (0.387) | 0.946 |
| Off-pump | 2 | 1.37 (0.67–2.80) | 0.87 | 0.386 | 56.1 (0.131) | NA |
| CPB time (min) | 3 | 0.20 (0.04–0.36) | 2.39 | 0.017 | 12.5 (0.319) | 0.422 |
| IV inotrope | 2 | 1.74 (1.50–2.02) | 7.37 | < 0.001 | 0.0 (0.551) | NA |
| Infection | 3 | 2.45 (0.78–7.66) | 1.54 | 0.123 | 68.38 (0.042) | 0.877 |
| Renal failure | 3 | 3.94 (1.70–9.16) | 3.19 | 0.001 | 0.0 (0.771) | 0.582 |
| Re-operation | 2 | 6.41 (1.75–23.42) | 2.81 | 0.005 | 0.0 (0.485) | NA |
| Mechanical ventilation (h) | 2 | 0.26 (− 0.03 to 0.54) | 1.78 | 0.076 | 0.0 (0.606) | NA |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, Ca++ channel blocker; CI, confidence interval; COPD, chronic obstructive pulmonary diseases; Cr, creatinine; CVD, cerebrovascular disease; IV, intravenous; LVEF, left ventricle ejection fraction; MI, myocardial infarction; NA, not available; OR, odds ratio; SMD, standardized mean difference
Fig. 2The forest plots of the significant risk factors for new-onset postoperative atrial fibrillation after coronary artery bypass grafting
Subgroup analysis of left ventricle ejection fraction according to study characteristics
| Group | No. of study | SMD (95% CI) | Z-value | I2% (p) | Q (p) | |
|---|---|---|---|---|---|---|
| All studies | 6 | − 0.43 (− 0.67 to − 0.18) | − 3.43 | 0.001 | 71.4 (0.004) | |
| Before 2010 | 2 | − 0.50 (− 0.80 to − 0.20) | − 3.28 | 0.001 | 0 (0.342) | 0.58 (0.448) |
| After 2010 | 4 | − 0.40 (− 0.72 to − 0.07) | − 2.38 | 0.017 | 81.2 (0.001) | |
| ≥ 200 | 2 | − 0.36 (− 0.93 to 0.21) | − 1.24 | 0.217 | 91.8 (< 0.001) | 1.65 (0.199) |
| < 200 | 4 | − 0.48 (− 0.69 to − 0.27) | − 4.54 | < 0.001 | 15.8 (0.313) | |
| Europe | 2 | − 0.16 (− 0.42 to 0.10) | − 1.21 | 0.228 | 31.2 (0.228) | 12.26 (< 0.001) |
| Asia | 4 | − 0.57 (− 0.76 to − 0.39) | − 6.04 | < 0.001 | 20.0 (0.289) |
CI, confidence interval; SMD, standardized mean difference